Perseid Achieves Preclinical Milestone Under Collaboration with Astellas for CTLA-4 Program

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a preclinical milestone under its collaboration with Astellas Pharma Inc. to co-develop and commercialize next-generation CTLA4-Ig therapeutics. Perseid has received a $5 million payment from Astellas for achievement of this milestone. “This milestone represent

For more information, please visit
http://www.businesswire.com/news/home/20100119005960/en

You need to login to post comments.

Feed last updated 1969/12/31 @7:00 PM

0 COMMENTS:

VOCAPIA and SYSTRAN demonstrate an automated speech translation solution at EUROSATORY 2016 - GlobeNewswire (press release) views: 1534

Instagram is adding automatic in-app text translation - The Verge views: 1523

Here’s a ‘Brand-New’ Massive Multilingual Dataset for Machine Translation views: 1516

F.A.Q. | Terms and conditions